Eli Lilly and CoXSWX:LLY 100 EV-to-FCF is 109.60 as of Jun. 26, 2026, which is 168% above its 10-year median of 40.87. GuruFocus rates XSWX:LLY with a GF Score™ of 100/100 and a GF Value™ of CHF1,111.74 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 562 Drug Manufacturers companies, Eli Lilly and Co ranks worse than 86.48% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Eli Lilly and Co's Enterprise Value is CHF904,366 Mil.
Eli Lilly and Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was CHF8,251 Mil. Therefore, Eli Lilly and Co's EV-to-FCF for today is 109.60.
The historical rank and industry rank for Eli Lilly and Co's EV-to-FCF or its related term are showing as below:
XSWX:LLY'
s EV-to-FCF Range Over the Past 10 Years
Min: -15201.83 Med: 40.87 Max: 2081.86
Current: 100.67
During the past 13 years, the highest EV-to-FCF of Eli Lilly and Co was 2081.86. The lowest was -15201.83. And the median was 40.87.
XSWX:LLY's EV-to-FCF is ranked worse than 86.48% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.11
vs XSWX:LLY: 100.67
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Eli Lilly and Co's PE Ratio (TTM) for today is calculated as:
Eli Lilly and Co's share price for today is CHF915.00.
Eli Lilly and Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF22.451.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Eli Lilly and Co EV-to-FCF Related Terms
Eli Lilly and Co EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Eli Lilly and Co's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eli Lilly and Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's EV-to-FCF falls into.
Eli Lilly and Co's current Enterprise Value is CHF904,366 Mil.
Eli Lilly and Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF8,251 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eli Lilly and Co (XSWX:LLY) has a EV-to-FCF of 109.60 as of Jun. 26, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Eli Lilly and Co and its competitors. This is 168% above median its historical median of 40.87. According to the industry distribution chart, Eli Lilly and Co ranks #486 out of 562 companies in the Drug Manufacturers industry, placing it in the top 86.5%.
Is Eli Lilly and Co's EV-to-FCF too high?
Eli Lilly and Co's current EV-to-FCF of 109.60 is 168% above median its 10-year median of 40.87. The Drug Manufacturers industry median EV-to-FCF is 20.11. Eli Lilly and Co's value of 109.60 is 445% above this industry median. Based on the distribution chart, Eli Lilly and Co ranks #486 out of 562 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Eli Lilly and Co has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's EV-to-FCF compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #486 out of 562 companies for EV-to-FCF. This places Eli Lilly and Co in the lower half of its industry. The industry median EV-to-FCF is 20.11. Eli Lilly and Co's value of 109.60 is 445% above this benchmark. While the company's 10-year median is 40.87 vs. the industry median of 20.11, Eli Lilly and Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.11, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eli Lilly and Co's current EV-to-FCF of 109.60 is 445% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Eli Lilly and Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current EV-to-FCF is 109.60, which is 168% above median its own 10-year median of 40.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,111.74, compared to a current price of CHF915.00 — trading 17.7% below its estimated fair value. The current EV-to-FCF is 109.60, which is 168% above median its 10-year median of 40.87 and 445% above the Drug Manufacturers industry median of 20.11. Eli Lilly and Co's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current EV-to-FCF is 109.60 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of CHF915.00 is trading 17.7% below its estimated GF Value™ of CHF1,111.74.
GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.
Key valuation signals for XSWX:LLY:
EV-to-FCF: 109.60 (168% above median its 10-year median of 40.87)
GF Value™: CHF1,111.74 vs. price of CHF915.00 (17.7% below fair value)
Industry Position: 445% above the Drug Manufacturers median (#486 of 562)
No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
100GF Score
Get the complete analysis for XSWX:LLY
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:LLY has been successfully added to your 
